Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28597762,inhalation times,Median inhalation times were considerably shorter with BREELIB versus I-Neb (2.6 versus 10.9 min; n = 24).,The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597762/),min,2.6,5427,DB01088,Iloprost
,28597762,inhalation times,Median inhalation times were considerably shorter with BREELIB versus I-Neb (2.6 versus 10.9 min; n = 24).,The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597762/),min,10.9,5428,DB01088,Iloprost
,9349930,steady-state plasma levels,"After i.v. infusion of iloprost, dose-normalized (3 ng.kg-1.min-1), steady-state plasma levels were 260 pg.",Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349930/),pg,260,9465,DB01088,Iloprost
,9349930,Terminal half-life,Terminal half-life was 0.57 h.,Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349930/),h,0.57,9466,DB01088,Iloprost
,9349930,Total clearance,Total clearance ranged from 8 to 17 ml.min-1.kg-1.,Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349930/),[ml] / [kg·min],8 to 17,9467,DB01088,Iloprost
,9349930,Absolute bioavailability,"Absolute bioavailability was 24%, with the exception of two patients who tolerated only 50 micrograms b.i.d. and exhibited a bioavailability of approx.",Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349930/),%,24,9468,DB01088,Iloprost
,2443364,Total radioactivity,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[equiv·pg] / [ml],408,12081,DB01088,Iloprost
,2443364,half-lives,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),min,24,12082,DB01088,Iloprost
,2443364,half-lives,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),h,1.7,12083,DB01088,Iloprost
,2443364,half-lives,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),h,5.0,12084,DB01088,Iloprost
,2443364,peak,A steady-state of unchanged iloprost was reached rapidly with a peak of 81 pg/ml.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[pg] / [ml],81,12085,DB01088,Iloprost
,2443364,half-lives,Plasma levels declined biphasically with half-lives of 6 min and 31 min.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),min,6,12086,DB01088,Iloprost
,2443364,half-lives,Plasma levels declined biphasically with half-lives of 6 min and 31 min.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),min,31,12087,DB01088,Iloprost
,2443364,Total clearance,Total clearance was 24 ml X min-1 X kg-1.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[ml] / [kg·min],24,12088,DB01088,Iloprost
,2443364,Maximum concentrations,"Maximum concentrations of labeled substances after oral administration were 307 and 1,051 pg equiv/ml after 29 and 39 min, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[equiv·pg] / [ml],307,12089,DB01088,Iloprost
,2443364,Maximum concentrations,"Maximum concentrations of labeled substances after oral administration were 307 and 1,051 pg equiv/ml after 29 and 39 min, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[equiv·pg] / [ml],"1,051",12090,DB01088,Iloprost
,2443364,peak,The peak of unchanged iloprost (116 pg/ml) was observed 7.5 min after an oral dose of 0.48 microgram/kg.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[pg] / [ml],116,12091,DB01088,Iloprost
,2443364,Bioavailability,Bioavailability was 16%.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),%,16,12092,DB01088,Iloprost
,2423342,steady-state plasma levels,"Following i.v. infusion, the steady-state plasma levels of iloprost were strictly dose-dependent (46 +/- 8 pg/ml and 135 +/- 24 pg/ml).",Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),[pg] / [ml],46,12353,DB01088,Iloprost
,2423342,steady-state plasma levels,"Following i.v. infusion, the steady-state plasma levels of iloprost were strictly dose-dependent (46 +/- 8 pg/ml and 135 +/- 24 pg/ml).",Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),[pg] / [ml],135,12354,DB01088,Iloprost
,2423342,half-lives,The disposition was biphasic with half-lives of 3-4 min and 0.5 h.,Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),min,3-4,12355,DB01088,Iloprost
,2423342,half-lives,The disposition was biphasic with half-lives of 3-4 min and 0.5 h.,Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),h,0.5,12356,DB01088,Iloprost
,2423342,maximum plasma level,"After oral administration, absorption of the drug was extremely rapid, the maximum plasma level of 251 +/- 32 pg/ml being achieved after 10 +/- 6 min.",Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),[pg] / [ml],251,12357,DB01088,Iloprost
,2423342,bioavailability,The bioavailability was 16 +/- 4%.,Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),%,16,12358,DB01088,Iloprost
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],407,17408,DB01088,Iloprost
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],294,17409,DB01088,Iloprost
,14555558,maximum serum concentrations,"Moreover, rapid entry of iloprost into the systemic circulation was noted, peaking immediately after termination of the inhalation maneuver, with very similar maximum serum concentrations (158 pg/mL, 155 pg/mL, and 157 pg/mL), and half-lives of serum levels (6.5 min, 9.4 min, and 7.7 min) for the three nebulizers, respectively.","Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555558/),[pg] / [ml],158,22838,DB01088,Iloprost
,14555558,maximum serum concentrations,"Moreover, rapid entry of iloprost into the systemic circulation was noted, peaking immediately after termination of the inhalation maneuver, with very similar maximum serum concentrations (158 pg/mL, 155 pg/mL, and 157 pg/mL), and half-lives of serum levels (6.5 min, 9.4 min, and 7.7 min) for the three nebulizers, respectively.","Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555558/),[pg] / [ml],155,22839,DB01088,Iloprost
,14555558,maximum serum concentrations,"Moreover, rapid entry of iloprost into the systemic circulation was noted, peaking immediately after termination of the inhalation maneuver, with very similar maximum serum concentrations (158 pg/mL, 155 pg/mL, and 157 pg/mL), and half-lives of serum levels (6.5 min, 9.4 min, and 7.7 min) for the three nebulizers, respectively.","Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555558/),[pg] / [ml],157,22840,DB01088,Iloprost
,14555558,half-lives of serum levels,"Moreover, rapid entry of iloprost into the systemic circulation was noted, peaking immediately after termination of the inhalation maneuver, with very similar maximum serum concentrations (158 pg/mL, 155 pg/mL, and 157 pg/mL), and half-lives of serum levels (6.5 min, 9.4 min, and 7.7 min) for the three nebulizers, respectively.","Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555558/),min,6.5,22841,DB01088,Iloprost
,14555558,half-lives of serum levels,"Moreover, rapid entry of iloprost into the systemic circulation was noted, peaking immediately after termination of the inhalation maneuver, with very similar maximum serum concentrations (158 pg/mL, 155 pg/mL, and 157 pg/mL), and half-lives of serum levels (6.5 min, 9.4 min, and 7.7 min) for the three nebulizers, respectively.","Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555558/),min,9.4,22842,DB01088,Iloprost
,14555558,half-lives of serum levels,"Moreover, rapid entry of iloprost into the systemic circulation was noted, peaking immediately after termination of the inhalation maneuver, with very similar maximum serum concentrations (158 pg/mL, 155 pg/mL, and 157 pg/mL), and half-lives of serum levels (6.5 min, 9.4 min, and 7.7 min) for the three nebulizers, respectively.","Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555558/),min,7.7,22843,DB01088,Iloprost
,6208562,half-life,After a rapid distribution phase the plasma level of radioactive substances declined with a half-life of 44 min.,"Pharmacokinetics and pharmacodynamics of the stable prostacyclin analogue, ZK 36 374, in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6208562/),min,44,26380,DB01088,Iloprost
,6208562,half-lives,The disposition of the unchanged drug was biphasic with half-lives of 7 min and 36 min.,"Pharmacokinetics and pharmacodynamics of the stable prostacyclin analogue, ZK 36 374, in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6208562/),min,7,26381,DB01088,Iloprost
,6208562,half-lives,The disposition of the unchanged drug was biphasic with half-lives of 7 min and 36 min.,"Pharmacokinetics and pharmacodynamics of the stable prostacyclin analogue, ZK 36 374, in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6208562/),min,36,26382,DB01088,Iloprost
,1706685,terminal half-life,"In volunteers and PAOD-patients the pharmacokinetics of iloprost after intravenous (i.v.) infusion treatment was characterized by dose-dependent steady-state plasma levels, a terminal half-life of approximately 20-30 min, and a total clearance of 15-20 ml/min/kg.",Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),min,20-30,50017,DB01088,Iloprost
,1706685,total clearance,"In volunteers and PAOD-patients the pharmacokinetics of iloprost after intravenous (i.v.) infusion treatment was characterized by dose-dependent steady-state plasma levels, a terminal half-life of approximately 20-30 min, and a total clearance of 15-20 ml/min/kg.",Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),[ml] / [kg·min],15-20,50018,DB01088,Iloprost
,1706685,steady-state levels,In the dialysis patients steady-state levels were 114 to 320 pg/ml as compared to 36 to 70 pg/ml in the non-dialysis group.,Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),[pg] / [ml],114 to 320,50019,DB01088,Iloprost
,1706685,steady-state levels,In the dialysis patients steady-state levels were 114 to 320 pg/ml as compared to 36 to 70 pg/ml in the non-dialysis group.,Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),[pg] / [ml],36 to 70,50020,DB01088,Iloprost
,1706685,Half-lives,Half-lives were similar in both groups: alpha-phase: 0.05 h and beta-phase: 0.5 h.,Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),h,0.05,50021,DB01088,Iloprost
,1706685,alpha-phase,Half-lives were similar in both groups: alpha-phase: 0.05 h and beta-phase: 0.5 h.,Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),h,0.05,50022,DB01088,Iloprost
,1706685,beta-phase,Half-lives were similar in both groups: alpha-phase: 0.05 h and beta-phase: 0.5 h.,Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),h,0.5,50023,DB01088,Iloprost
,1706685,total clearance,The total clearance was 2.6 to 8.0 ml/min/kg (dialysis patients) and 13.2 to 25.8 ml/min/kg (non-dialysis patients).,Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),[ml] / [kg·min],2.6 to 8.0,50024,DB01088,Iloprost
,1706685,total clearance,The total clearance was 2.6 to 8.0 ml/min/kg (dialysis patients) and 13.2 to 25.8 ml/min/kg (non-dialysis patients).,Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706685/),[ml] / [kg·min],13.2 to 25.8,50025,DB01088,Iloprost
,1281921,Disposition half-lives,Disposition half-lives were 3 and 14 min.,Pharmacokinetics of iloprost and cicaprost in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),min,3,70550,DB01088,Iloprost
,1281921,Disposition half-lives,Disposition half-lives were 3 and 14 min.,Pharmacokinetics of iloprost and cicaprost in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),min,14,70551,DB01088,Iloprost
,1281921,Total clerance,Total clerance accounted for 152 ml/min/kg.,Pharmacokinetics of iloprost and cicaprost in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ml] / [kg·min],152,70552,DB01088,Iloprost
,1281921,clearance,"Total radiolabel exhibited a clearance of 35 ml/min/kg, its AUC in plasma was 146 ng-equiv.h/ml.",Pharmacokinetics of iloprost and cicaprost in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ml] / [kg·min],35,70553,DB01088,Iloprost
,1281921,AUC,"Total radiolabel exhibited a clearance of 35 ml/min/kg, its AUC in plasma was 146 ng-equiv.h/ml.",Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[h·ng-equiv] / [ml],146,70554,DB01088,Iloprost
,1281921,peak plasma levels,After ig administration Iloprost peak plasma levels of 9.2 ng/ml occurred after 5 min.,Pharmacokinetics of iloprost and cicaprost in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ng] / [ml],9.2,70555,DB01088,Iloprost
,1281921,Bioavailability,Bioavailability was 10%.,Pharmacokinetics of iloprost and cicaprost in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,10,70556,DB01088,Iloprost
,1281921,AUC,"AUC of total radiolabel was 152 ng-equiv.h/ml, showing complete absorption.",Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[h·ng-equiv] / [ml],152,70557,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,41,70558,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,57,70559,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,36,70560,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,47,70561,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,32,70562,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,18,70563,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,36,70564,DB01088,Iloprost
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,25,70565,DB01088,Iloprost
,1281921,half-lives,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),d,0.2-0.3,70566,DB01088,Iloprost
,1281921,AUC,Extrapolated AUC was 1.6 ng-equiv.,Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),ng-equiv,1.6,70567,DB01088,Iloprost
,1281921,total clearance,h/ml and total clearance accounted for 108 ml/min/kg.,Pharmacokinetics of iloprost and cicaprost in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ml] / [kg·min],108,70568,DB01088,Iloprost
,1281921,peak radioactivity plasma levels,"After ig treatment peak radioactivity plasma levels of 0.7 and 1 ng-equiv./ml were observed at 0.16 and 1 h postdose, probably due to differences between animal groups.",Pharmacokinetics of iloprost and cicaprost in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ng-equiv] / [ml],0.7,70569,DB01088,Iloprost
,1281921,peak radioactivity plasma levels,"After ig treatment peak radioactivity plasma levels of 0.7 and 1 ng-equiv./ml were observed at 0.16 and 1 h postdose, probably due to differences between animal groups.",Pharmacokinetics of iloprost and cicaprost in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ng-equiv] / [ml],1,70570,DB01088,Iloprost
,1281921,AUC,Extrapolated AUC was 1 ng-equiv.h/ml.,Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[h·ng-equiv] / [ml],1,70571,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,83,70572,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,89,70573,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,93,70574,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,92,70575,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,8.3,70576,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,5.7,70577,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,2.6,70578,DB01088,Iloprost
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,5.5,70579,DB01088,Iloprost
,1370924,Steady-state plasma iloprost concentration,Steady-state plasma iloprost concentration was 591 +/- 64 pmol/l.,Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[pM] / [l],591,120742,DB01088,Iloprost
,1370924,Steady-state clearance,"Steady-state clearance of t-PA was unchanged by iloprost (454 +/- 65 versus 443 +/- 136 ml/min in controls, p = NS).",Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[ml] / [min],454,120743,DB01088,Iloprost
,1370924,Steady-state clearance,"Steady-state clearance of t-PA was unchanged by iloprost (454 +/- 65 versus 443 +/- 136 ml/min in controls, p = NS).",Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[ml] / [min],443,120744,DB01088,Iloprost
,17034310,maximum intravascular concentrations,"Similarly, dose-dependent appearance of iloprost in the recirculating perfusate was noted, with maximum intravascular concentrations of iloprost ranging at 140, 510, and 1163 pg/mL at the same time period.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),[pg] / [ml],140,130012,DB01088,Iloprost
,17034310,maximum intravascular concentrations,"Similarly, dose-dependent appearance of iloprost in the recirculating perfusate was noted, with maximum intravascular concentrations of iloprost ranging at 140, 510, and 1163 pg/mL at the same time period.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),[pg] / [ml],510,130013,DB01088,Iloprost
,17034310,maximum intravascular concentrations,"Similarly, dose-dependent appearance of iloprost in the recirculating perfusate was noted, with maximum intravascular concentrations of iloprost ranging at 140, 510, and 1163 pg/mL at the same time period.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),[pg] / [ml],1163,130014,DB01088,Iloprost
,17034310,bioavailability,"(i) The bioavailability (i.e., the percentage of aerosolized iloprost appearing intravascularly) decreased from 76% at the lowest to 33% at the highest iloprost dosage.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),%,76,130015,DB01088,Iloprost
,17034310,bioavailability,"(i) The bioavailability (i.e., the percentage of aerosolized iloprost appearing intravascularly) decreased from 76% at the lowest to 33% at the highest iloprost dosage.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),%,33,130016,DB01088,Iloprost
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),min,45,152625,DB01088,Iloprost
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),h,4.3,152626,DB01088,Iloprost
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),d,1.7,152627,DB01088,Iloprost
,6193537,half-life,The half-life of the unchanged drug was 13 min.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),min,13,152628,DB01088,Iloprost
,6193537,maximum plasma levels,Almost 10% of an oral dose of 200 microgram/kg were bioavailable exhibiting maximum plasma levels of 5.7 +/- 3.6 ng/ml.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),[ng] / [ml],5.7,152629,DB01088,Iloprost
,1700723,Dose-normalized steady-state plasma levels,Dose-normalized steady-state plasma levels ranged from 39 to 100 pg/ml (65 +/- 20 pg/ml).,Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1700723/),[pg] / [ml],39 to 100,158713,DB01088,Iloprost
,1700723,Dose-normalized steady-state plasma levels,Dose-normalized steady-state plasma levels ranged from 39 to 100 pg/ml (65 +/- 20 pg/ml).,Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1700723/),[pg] / [ml],65,158714,DB01088,Iloprost
,1700723,total clearance,The total clearance accounted for 16 +/- 5 ml/min/kg.,Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1700723/),[ml] / [kg·min],16,158715,DB01088,Iloprost
,1700723,half-lives,Post-infusion disposition in the plasma was biphasic with half-lives of 4 +/- 2 min and 37 +/- 8 min.,Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1700723/),min,4,158716,DB01088,Iloprost
,1700723,half-lives,Post-infusion disposition in the plasma was biphasic with half-lives of 4 +/- 2 min and 37 +/- 8 min.,Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1700723/),min,37,158717,DB01088,Iloprost
,9175177,plasma level,There was a high initial iloprost plasma level (mean 625 pg/ml) which dropped to a mean of 50 pg/ml after 15 min.,Pharmacokinetics and pharmacodynamics of intra-graft iloprost in femorodistal bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175177/),[pg] / [ml],625,166252,DB01088,Iloprost
,9175177,plasma level,There was a high initial iloprost plasma level (mean 625 pg/ml) which dropped to a mean of 50 pg/ml after 15 min.,Pharmacokinetics and pharmacodynamics of intra-graft iloprost in femorodistal bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175177/),p,50,166253,DB01088,Iloprost
,7692471,Total clearance,"Total clearance of the pro-drug accounted for 170, 62 and 66 ml/min/kg in rat, monkey and man.",Bioactivation of eptaloprost in animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),[ml] / [kg·min],170,180634,DB01088,Iloprost
,7692471,Total clearance,"Total clearance of the pro-drug accounted for 170, 62 and 66 ml/min/kg in rat, monkey and man.",Bioactivation of eptaloprost in animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),[ml] / [kg·min],62,180635,DB01088,Iloprost
,7692471,Total clearance,"Total clearance of the pro-drug accounted for 170, 62 and 66 ml/min/kg in rat, monkey and man.",Bioactivation of eptaloprost in animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),[ml] / [kg·min],66,180636,DB01088,Iloprost
,7692471,half-lives,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.1 to 0.5,180637,DB01088,Iloprost
,7692471,mean residence times,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.15,180638,DB01088,Iloprost
,7692471,mean residence times,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.4,180639,DB01088,Iloprost
,7692471,mean residence times,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.6,180640,DB01088,Iloprost
,1701761,Steady state plasma levels,Steady state plasma levels of 93 +/- 31 pg/ml were observed at the end of infusion.,Pharmacokinetics of iloprost in patients with hepatic dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1701761/),[pg] / [ml],93,185811,DB01088,Iloprost
,1701761,terminal half-life,The terminal half-life of iloprost was 28 +/- 24 min.,Pharmacokinetics of iloprost in patients with hepatic dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1701761/),min,28,185812,DB01088,Iloprost
,1701761,AUC,From AUC values of 126 +/- 60 pg.h/ml a total clearance of 10 +/- 5 ml/min/kg was calculated.,Pharmacokinetics of iloprost in patients with hepatic dysfunction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1701761/),[h·pg] / [ml],126,185813,DB01088,Iloprost
,1701761,total clearance,From AUC values of 126 +/- 60 pg.h/ml a total clearance of 10 +/- 5 ml/min/kg was calculated.,Pharmacokinetics of iloprost in patients with hepatic dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1701761/),[ml] / [kg·min],10,185814,DB01088,Iloprost
,6189134,limit of detection,The limit of detection is 0.5 ng/ml.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),[ng] / [ml],0.5,195881,DB01088,Iloprost
,6189134,half-lives,After intravenous administration of 200 micrograms/kg to female Wistar rats a biphasic decline of the drug concentration in the plasma was observed with half-lives of 5 min and 3 h.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),min,5,195882,DB01088,Iloprost
,6189134,half-lives,After intravenous administration of 200 micrograms/kg to female Wistar rats a biphasic decline of the drug concentration in the plasma was observed with half-lives of 5 min and 3 h.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),h,3,195883,DB01088,Iloprost
,6189134,maximum plasma levels,Oral doses of 200 and 2000 micrograms/kg were very rapidly absorbed reaching maximum plasma levels of 3 and 32 ng/ml as early as 10-15 min p.admin..,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),[ng] / [ml],3,195884,DB01088,Iloprost
,6189134,maximum plasma levels,Oral doses of 200 and 2000 micrograms/kg were very rapidly absorbed reaching maximum plasma levels of 3 and 32 ng/ml as early as 10-15 min p.admin..,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),[ng] / [ml],32,195885,DB01088,Iloprost
,6189134,Bioavailability,Bioavailability at the two dose levels was calculated to be 8 and 13% of dose.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),%,8,195886,DB01088,Iloprost
,6189134,Bioavailability,Bioavailability at the two dose levels was calculated to be 8 and 13% of dose.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),%,13,195887,DB01088,Iloprost
,6201926,bioavailability,The bioavailability was estimated as about 10% of the dose.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),%,10,226715,DB01088,Iloprost
,6201926,half-lives,"The concentration of radio-labelled compounds in the plasma declined in three phases with half-lives of 3 min, 46 min and approx.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),min,3,226716,DB01088,Iloprost
,6201926,half-lives,"The concentration of radio-labelled compounds in the plasma declined in three phases with half-lives of 3 min, 46 min and approx.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),min,46,226717,DB01088,Iloprost
,6201926,half-life,The half-life of the unchanged drug was 14 min.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),min,14,226718,DB01088,Iloprost
,12388660,half-life,"After buffer admixture of iloprost, a steady decline of perfusate concentrations of the intact prostanoid was noted (half-life approximately 3.5 h), mostly attributable to progressive metabolism to dinor- and tetranoriloprost.",Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12388660/),h,3.5,258803,DB01088,Iloprost
,12388660,bioavailability,"Inhaled iloprost rapidly entered the intravascular compartment, with peak buffer concentrations being noted after 30 min (bioavailability approximately 63%).",Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12388660/),%,63,258804,DB01088,Iloprost
